MXCT - Cell Engineering MaxCyte Faces Challenge Analysts Express Concerns Over Near-Term Prospects Amid Revenue Decline | Benzinga
MaxCyte Inc (NASDAQ: MXCT) shares plummeted after the company released preliminary Q3 revenue of $7.8 million – 8.0 million, a Y/Y decrease of 25 -27%, due to continued reduced customer activity in the sector.
The company sees Q3 core business revenue of $6.4 million-$6.6 million, down 33% - 35% Y/Y.
For FY23, MaxCyte sees total sales of approximately $34 - 36 million, below the consensus of $35 million.
Core revenue is now expected to be approximately $28 - 30 million. Earlier, the company expected core revenue for 2023 to be comparable to ...